Table 2.

Demographic, clinical, and magnetization transfer ratio characteristics of the relapsing remitting and progressive multiple sclerosis patients.

	RRMS (n=69)	SPMS (n=32)	p-value	BH-adjusted p-value
Female, n (%)	51 (73.9%)	24 (75.0%)	1.000	1.000
Age, mean (SD)	44.4 (10.0)	52.3 (8.7)	<0.001	0.001
Disease duration, mean (SD)	10.2 (8.4)	19.9 (12.8)	<0.001	0.002
EDSS, median (IQR)	2.0 (1.5–2.5)	6.0 (4.5–6.5)	<0.001	<0.001
Anti-EBNA-1 titer	132.6 (49.5–279.9)	80.4 (41.2–217.0)	0.317	0.635
	MTR outcomes measures
T2 lesion MTR	41.0 (36.0–44.0)	42.0 (35.0–43.0)	0.909	0.957
T1 lesion MTR	35.0 (33.0–37.5)	35.0 (32.0–38.0)	0.694	0.992
NABT MTR	41.0 (36.5–42.0)	40.0 (37.0–41.0)	0.476	0.865
NAWM MTR	44.0 (38.0–46.0)	44.0 (39.3–45.0)	0.727	0.808
NAGM MTR	37.0 (34.0–38.5)	36.5 (34.3–38.0)	0.269	0.599

RRMS – relapsing-remitting multiple sclerosis, SPMS – secondary-progressive multiple sclerosis, BH – Benjamini-Hochberg, EDSS – Extended Disability Status Scale, EBV – Epstein-Barr virus, EBNA-1 – Epstein-Barr nuclear antigen-1, MTR – magnetization transfer ratio, NABT – normal appearing brain tissue, NAWM – normal appearing white matter, NAGM – normal appearing gray matter.

The MTR and EBV response measures are shown as median (IQR). χ², Student’s t-test, and Mann Whitney U-test were used accordingly. Benjamini-Hochberg-adjusted p values < 0.05 were considered significant.

Comparison of patients scanned only on 3T scanner yielded similar statistical differences.